- Home
- ACRS vs UFG Comparison
ACRS vs UFG Comparison
Compare ACRS & UFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- UFG
- Stock Information
- Founded
- ACRS 2012
- UFG 2021
- Country
- ACRS United States
- UFG Singapore
- Employees
- ACRS N/A
- UFG N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- UFG Oil Refining/Marketing
- Sector
- ACRS Health Care
- UFG Energy
- Exchange
- ACRS Nasdaq
- UFG Nasdaq
- Market Cap
- ACRS 132.0M
- UFG 136.4M
- IPO Year
- ACRS 2015
- UFG 2025
- Fundamental
- Price
- ACRS $2.60
- UFG N/A
- Analyst Decision
- ACRS Strong Buy
- UFG
- Analyst Count
- ACRS 5
- UFG 0
- Target Price
- ACRS $11.00
- UFG N/A
- AVG Volume (30 Days)
- ACRS 956.3K
- UFG 500.0K
- Earning Date
- ACRS 02-25-2025
- UFG 01-01-0001
- Dividend Yield
- ACRS N/A
- UFG N/A
- EPS Growth
- ACRS N/A
- UFG N/A
- EPS
- ACRS N/A
- UFG 0.02
- Revenue
- ACRS $27,079,000.00
- UFG $130,669,390.00
- Revenue This Year
- ACRS N/A
- UFG N/A
- Revenue Next Year
- ACRS N/A
- UFG N/A
- P/E Ratio
- ACRS N/A
- UFG $223.55
- Revenue Growth
- ACRS 26.35
- UFG 129.69
- 52 Week Low
- ACRS $0.95
- UFG $3.82
- 52 Week High
- ACRS $5.17
- UFG $4.75
- Technical
- Relative Strength Index (RSI)
- ACRS 44.33
- UFG N/A
- Support Level
- ACRS $2.31
- UFG N/A
- Resistance Level
- ACRS $2.64
- UFG N/A
- Average True Range (ATR)
- ACRS 0.16
- UFG 0.00
- MACD
- ACRS 0.02
- UFG 0.00
- Stochastic Oscillator
- ACRS 58.76
- UFG 0.00
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.